Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D001088:Arabinonucleotides / Q000378:metabolism; D001853:Bone Marrow / Q000187:drug effects; D002460:Cell Line; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005260:Female; D007413:Intestinal Mucosa / Q000187:drug effects; D007942:Leukemia, Experimental / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D012263:Ribonucleosides / Q000494:pharmacology*; D013997:Time Factors; D014740:Vidarabine / Q000008:administration & dosage*
D058892:Adenosine Deaminase Inhibitors; D001088:Arabinonucleotides; D004273:DNA, Neoplasm; D012263:Ribonucleosides; D003070:Coformycin; D009700:Nucleoside Deaminases; D014740:Vidarabine; D000225:Adenine